Aardvark Therapeutics (AARD) Competitors $13.52 -0.04 (-0.29%) As of 07/2/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. TVTX, BGM, GPCR, CVAC, CALT, DYN, ABCL, AMPH, AUPH, and WVEShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), Amphastar Pharmaceuticals (AMPH), Aurinia Pharmaceuticals (AUPH), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Travere Therapeutics BGM Group Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Dyne Therapeutics AbCellera Biologics Amphastar Pharmaceuticals Aurinia Pharmaceuticals WAVE Life Sciences Aardvark Therapeutics (NASDAQ:AARD) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Does the media prefer AARD or TVTX? In the previous week, Aardvark Therapeutics had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 10 mentions for Aardvark Therapeutics and 9 mentions for Travere Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.79 beat Travere Therapeutics' score of 0.42 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend AARD or TVTX? Aardvark Therapeutics currently has a consensus target price of $33.00, suggesting a potential upside of 144.08%. Travere Therapeutics has a consensus target price of $32.14, suggesting a potential upside of 116.60%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87 Is AARD or TVTX more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -82.88%. Aardvark Therapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Travere Therapeutics -82.88%-1,179.73%-41.10% Which has preferable valuation & earnings, AARD or TVTX? Aardvark Therapeutics has higher earnings, but lower revenue than Travere Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/A-$20.59MN/AN/ATravere Therapeutics$233.18M5.65-$321.55M-$2.81-5.28 SummaryAardvark Therapeutics beats Travere Therapeutics on 8 of the 10 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$294.20M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E RatioN/A21.3126.1719.90Price / SalesN/A278.47413.55113.66Price / CashN/A41.4736.1356.90Price / BookN/A7.518.025.38Net Income-$20.59M-$55.05M$3.15B$248.50M7 Day Performance-2.45%2.07%1.48%2.06%1 Month Performance15.95%4.84%3.66%4.86%1 Year PerformanceN/A5.37%34.68%20.24% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$13.52-0.3%$33.00+144.1%N/A$294.20MN/A0.0018News CoverageAnalyst ForecastAnalyst RevisionTVTXTravere Therapeutics3.2134 of 5 stars$15.13+1.3%$32.14+112.4%+83.4%$1.33B$233.18M-5.38460Analyst ForecastBGMBGM GroupN/A$12.82-1.4%N/AN/A$1.26B$25.10M0.00298High Trading VolumeGPCRStructure Therapeutics2.7073 of 5 stars$21.08-3.3%$76.17+261.3%-47.2%$1.25BN/A-24.23136CVACCureVac4.7038 of 5 stars$5.40-0.7%$6.83+26.5%+61.7%$1.22B$579.18M5.87880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180DYNDyne Therapeutics3.5062 of 5 stars$10.05-3.6%$41.13+309.2%-74.2%$1.18BN/A-2.80100ABCLAbCellera Biologics2.2536 of 5 stars$3.74-1.6%$8.33+122.8%+35.4%$1.13B$28.83M-6.68500AMPHAmphastar Pharmaceuticals4.2856 of 5 stars$23.18-1.2%$32.33+39.5%-37.3%$1.11B$731.97M8.402,028AUPHAurinia Pharmaceuticals2.7144 of 5 stars$8.63+7.5%$11.50+33.3%+37.9%$1.08B$235.13M30.82300Positive NewsHigh Trading VolumeWVEWAVE Life Sciences4.544 of 5 stars$7.03+2.6%$20.50+191.6%+29.3%$1.07B$108.30M-8.37240Positive News Related Companies and Tools Related Companies TVTX Alternatives BGM Alternatives GPCR Alternatives CVAC Alternatives CALT Alternatives DYN Alternatives ABCL Alternatives AMPH Alternatives AUPH Alternatives WVE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
